Advancing cell & gene therapy – optimizing lentiviral vector design and production
To meet the demand for innovative treatments based on cell and gene therapy, it’s essential that we deliver solutions that are both faster and more cost-effective. Optimizing lentiviral vector (LVV) design and production is critical for advancing a subset of these therapies like CAR-T.
What are some of the main challenges? How can we boost LVV yield and enhance safety profiles? What insights can we gain from viral vector production applied in other areas like vaccines and gene therapy?
Join the J&J Innovation – JLABS program as we delve into the latest advancements in lentiviral vector design and production.
Register here: https://lentiviral.splashthat.com/nl
Openingstijden
- Woensdag 27 november 2024 14.00 - 18.00 uur